An Update on Topical Therapies for Mild-Moderate Psoriasis

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 73-77

  van de Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Calcipotriol; Calcitriol; Corticosteroids; Ditranol; Small molecules; Tar; Tazarotene

Indexed keywords

ANTIPSORIASIS AGENT; BETAMETHASONE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID DERIVATIVE; DITHRANOL; RETINOID DERIVATIVE; VITAMIN D; ANTIINFLAMMATORY AGENT; COAL TAR; COLECALCIFEROL; CORTICOSTEROID; DERMATOLOGICAL AGENT; PROTEIN KINASE INHIBITOR; RETINOID; VITAMIN;

CHRONIC DRUG ADMINISTRATION; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; OINTMENT; PRACTICE GUIDELINE; PSORIASIS; REVIEW; TOPICAL TREATMENT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DRUG COMBINATION; INTRADERMAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; CHOLECALCIFEROL; COAL TAR; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PROTEIN KINASE INHIBITORS; PSORIASIS; RETINOIDS; SEVERITY OF ILLNESS INDEX; VITAMINS;

EID: 84911480268     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.006     Document Type: Review

References (36)

1. van de Kerkhof P.C., Kragballe K., Segaert S., International Psoriasis Council, et al. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. JEur Acad Dermatol Venereol 2011, 25:1130-1139.
2. Feldman S.R., Horn E.J., Balkrishnan R., et al. Psoriasis: improving adherence to topical therapy. JAm Acad Dermatol 2008, 59:1009-1016.
3. van de Kerkhof P.C., Hoffmann V., Anstey A., et al. Anew scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009, 160:170-176.
4. Mason A.R., Mason J., Cork M., et al. Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review. JAm Acad Dermatol 2013, 69:799-807.
5. Samarasekera E.A., Sawyer L., Wonderling D., et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol 2013, 168:954-967.
6. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3: guidelines of care for the management and treatment of psoriasis with topical therapies. JAm Acad Dermatol 2009, 60:643-659.
7. Hendriks A.G., Keijsers R.R., de Jong E.M., et al. Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. JEur Acad Dermatol Venereol 2013, 27:399-410.
8. van de Kerkhof P.C. Dithranol treatment for psoriasis: after 75 years, still going strong. Eur J Dermatol 1991, 1:79-88.
9. Swinkels O.Q., Prins M., Veenhuis R.T., et al. Acare instruction programme of short contact dithranol in moderate to severe psoriasis. Eur J Dermatol 2004, 14:159-165.
10. van den Bogaard E.H., Bergboer J.G., Vonk-Bergers M., et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. JClin Invest 2013, 123:917-927.
11. Roelofzen J.H., Aben K.K., Oldenhof U.T., et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. JInvest Dermatol 2010, 130:953-961.
12. Hendriks A.G., Keijsers R.R., de Jong E.M., et al. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. JEur Acad Dermatol Venereol 2013, 27:931-951.
13. Kragballe K. Vitamin D in dermatology 2000, Marcel Dekker, New York.
14. Kowalzick L. Clinical experience with topical calcitriol (1,25 dihydroxyvitamin D3) in psoriasis. Br J Dermatol 2001, 144(Suppl 58):21-25.
15. Roeder A., Schaller M., Schafer-Korting M., et al. Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol 2005, 18:3-11.
16. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. JAm Acad Dermatol 2005, 53:S39-S49.
17. Feldman S.R., Yentzer B.A. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol 2009, 10:397-406.
18. Katz H.I., Hien N.T., Prower S.E., et al. Betamethasone in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987, 123:1308-1311.
19. Jarratt M.T., Clark S.D., Savin R.C., et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006, 78:348-354.
20. Menter A. Topical monotherapy with clobetasol propionate spray0.05% in the COBRA trial. Cutis 2000, 80:12-19.
21. Gottlieb A.B., Ford R.O., Spellman M.C. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. JCutan Med Surg 2003, 7:185-192.
22. Reid D.C., Kimball A.B. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005, 6:1735-1740.
23. Poulin Y., Papp K., Bissonnette R., et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. JDermatolog Treat 2010, 21:185-192.
24. Bovenschen H., Van de Kerkhof P. Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo: a study on daily clinical practice. JEur Acad Dermatol Venereol 2010, 24:439-444.
25. Sanchez Regana M., Martin Ezquerra G., Umbert Millet P., et al. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. JEur Acad Dermatol Venereol 2005, 19:573-577.
26. Feldman S.R. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work?. Clin Dermatol 2006, 24:229-230.
27. Lew-kaya D.A., Sefton J., Krueger F.F., et al. Safety and efficacy of a new retinoid gel in the treatment of psoriasis. JInvest Dermatol 1992, 98:600.
28. Gribetz C., Ling M., Lebwohl M., et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double blind, randomized study. JAm Acad Dermatol 2004, 51:731-738.
29. Kragballe K., Hoffmann V., Ortonne J.P., et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009, 161:159-166.
30. Luger T.A., Cambazard F., Larsen F.G., et al. Astudy of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008, 217:321-328.
31. Bos J.D., Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000, 9:165-169.
32. Bissonnette R., Bolduc C., Maari S., et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. JEur Acad Dermatol Venereol 2012, 26:1516-1521.
33. Miyoshi K., Takaishi M., Nakajima K.J., et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. JInvest Dermatol 2011, 131:108-117.
34. Moustafa F., Feldman S.R. Areview of phosphodiesterase-inhibition and the potential role for phosphodiesterase-E4 inhibitors in clinical dermatology. Dermatol Online J 2014, 20:22608.
35. Ports W.C., Khan S., Lan S., et al. Arandomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013, 169:137-145.
36. Punwani N., Scherle P., Flores R., et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. JAm Acad Dermatol 2012, 67:658-664.